Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

46.72 -0.06 (-0.13%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,382,095
Open 46.64
Bid (Size) 46.54 (100)
Ask (Size) 46.80 (500)
Prev. Close 46.78
Today's Range 46.48 - 46.97
52wk Range 43.32 - 55.77
Shares Outstanding 1,250,690,553
Dividend Yield 4.73%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly
INDIANAPOLIS – In a move that has left some retail investors scratching their heads, shares of Eli Lilly and Company (NYSE:LLY) have trended lower this week, despite the pharmaceutical giant releasing... 
Via MarketMinute
News headline image
AstraZeneca (AZN) Shares Rally After Breakthrough Chronic Lung Disease Trial Results
AstraZeneca (NASDAQ: AZN) shares climbed 2.7% in early trading today, March 27, 2026, following the release of highly anticipated Phase 3 clinical trial results for its latest respiratory blockbuster... 
Via MarketMinute
Topics Intellectual Property

Performance

YTD
-3.1%
-3.1%
1 Month
-4.0%
-4.0%
3 Month
-3.4%
-3.4%
6 Month
+2.3%
+2.3%
1 Year
-15.8%
-15.8%

More News

Read More
News headline image
Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data
Via MarketMinute
Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case ↗
Via Chartmill
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
Via Finterra
Topics Economy Initial Public Offering
News headline image
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Does This $25 Million Bet on a Stock Down 61% Signal Turnaround Potential at $6? ↗
Via The Motley Fool
Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening ↗
Via Chartmill
News headline image
The mRNA Renaissance: Moderna’s 83% Surge Leads the 2026 Healthcare Recovery
Via MarketMinute
Topics Artificial Intelligence Initial Public Offering Stocks
News headline image
Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
Via Finterra
Topics Economy
News headline image
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
Via Stocktwits
News headline image
The Moderna Pivot: Analyzing the 14% Surge and the Future of mRNA Oncology
Via Finterra
Topics Initial Public Offering Intellectual Property
News headline image
The Best Healthcare Stock to Invest $1,000 in Right Now ↗
Via The Motley Fool
News headline image
The Great Pivot: Inside Novavax’s 2026 Turnaround and the Road to Combination Vaccines
Via Finterra
Topics Economy
News headline image
AstraZeneca’s Strategic Leap: Pharmaceutical Giant Completes Historic Move to the New York Stock Exchange
Via MarketMinute
Topics ETFs
News headline image
European Commission Grants Marketing Authorization to Cytokinetics for Cardiac Drug MYQORZO
Via MarketMinute
Topics Intellectual Property
News headline image
1 No-Brainer Biotech Stock To Buy Today and Never Sell ↗
Via The Motley Fool
News headline image
Moderna’s mRNA Renaissance: Navigating Volatility and the Post-Pandemic Pipeline
Via Finterra
Topics Economy Intellectual Property
News headline image
Sanofi Tightens Grip on Ocular Therapeutix with Revised Bid as Pivotal SOL-1 Trial Results Loom
Via MarketMinute
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
Via Finterra
Topics Economy Intellectual Property
News headline image
FDA Stuns Moderna with Refusal to Review Flu Vaccine, Sending Shares Tumbling 3.5%
Via MarketMinute
Topics Earnings
News headline image
This Infrastructure Stock Surged Nearly 40% in One Year -- and One Fund Sold $11 Million in Shares ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Lilly Bolsters Immunology Arsenal with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute
News headline image
Eli Lilly Reinforces Immunology Dominance with $1.2 Billion Acquisition of Ventyx Biosciences
Via MarketMinute
News headline image
Nasdaq, S&P 500 Futures Subdued Ahead Of PMI Data: Why INTC, TSLA, NFLX, VST, MOVE Are On Traders' Radar Today ↗
Via Stocktwits
Topics ETFs Government Lawsuit

Frequently Asked Questions

Is Sanofi - American Depositary Shares publicly traded?
Yes, Sanofi - American Depositary Shares is publicly traded.
What exchange does Sanofi - American Depositary Shares trade on?
Sanofi - American Depositary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Sanofi - American Depositary Shares?
The ticker symbol for Sanofi - American Depositary Shares is SNY on the Nasdaq Stock Market
What is the current price of Sanofi - American Depositary Shares?
The current price of Sanofi - American Depositary Shares is 46.72
When was Sanofi - American Depositary Shares last traded?
The last trade of Sanofi - American Depositary Shares was at 03/30/26 04:00 PM ET
What is the market capitalization of Sanofi - American Depositary Shares?
The market capitalization of Sanofi - American Depositary Shares is 58.43B
How many shares of Sanofi - American Depositary Shares are outstanding?
Sanofi - American Depositary Shares has 58B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.